A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes

I8B-MC-ITSZ -

The reason for this study is to evaluate the amount of time with glucose values within target range.

Trial Summary

Age Range
18 - 65 years
Conditions the trial is for
Type 1 Diabetes
What the trial is testing?
Insulin Degludec, LY900014
Could I receive a Placebo?
No
Enrollment Goal
31
Trial Dates
Oct 30, 2020 - May 27, 2021
How long will I be in the trial?
The study will last about 74 days and may include up to 15 visits.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have type 1 diabetes and have been treated with insulin therapy for at least 1 year

  • Participants must be using Dexcom G5 or G6 Continuous Glucose Monitoring (CGM) and with a total CGM use 6 months in the prior year

  • Participants must have been on the same type of short acting insulin (Humalog U-100 or Novolog) for at least 30 days prior to screening

  • Participants must have been treated with long-acting insulin degludec U-100 for at least 30 days prior to screening

Participants Must Not:

  • Participants must not have had more than 1 emergency room visit or hospitalization due to poor glucose control within 6 months before screening

  • Participants must not have had more than 1 episode of severe hypoglycemia within the last 90 days prior to screening

  • Participants must not be taking certain diabetes medications that are not allowed for study participation

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.